nodes	percent_of_prediction	percent_of_DWPC	metapath
Dabrafenib—SLCO1B3—Mycophenolate mofetil—systemic lupus erythematosus	0.0731	0.113	CbGbCtD
Dabrafenib—ABCG2—Leflunomide—systemic lupus erythematosus	0.0548	0.085	CbGbCtD
Dabrafenib—SLCO1B1—Mycophenolate mofetil—systemic lupus erythematosus	0.0426	0.0661	CbGbCtD
Dabrafenib—ABCG2—Mycophenolate mofetil—systemic lupus erythematosus	0.0338	0.0525	CbGbCtD
Dabrafenib—SLCO1B1—Cyclosporine—systemic lupus erythematosus	0.0323	0.0501	CbGbCtD
Dabrafenib—SLCO1B3—Methotrexate—systemic lupus erythematosus	0.0293	0.0455	CbGbCtD
Dabrafenib—ABCG2—Hydrocortisone—systemic lupus erythematosus	0.0271	0.0421	CbGbCtD
Dabrafenib—ABCG2—Cyclosporine—systemic lupus erythematosus	0.0256	0.0398	CbGbCtD
Dabrafenib—CYP2C8—Dapsone—systemic lupus erythematosus	0.0208	0.0323	CbGbCtD
Dabrafenib—SLC22A6—Cyclosporine—systemic lupus erythematosus	0.0208	0.0322	CbGbCtD
Dabrafenib—CYP2C8—Mycophenolate mofetil—systemic lupus erythematosus	0.018	0.028	CbGbCtD
Dabrafenib—SLCO1B1—Methotrexate—systemic lupus erythematosus	0.0171	0.0265	CbGbCtD
Dabrafenib—ABCG2—Dexamethasone—systemic lupus erythematosus	0.0169	0.0262	CbGbCtD
Dabrafenib—ABCB1—Methylprednisolone—systemic lupus erythematosus	0.0161	0.025	CbGbCtD
Dabrafenib—SLC22A8—Methotrexate—systemic lupus erythematosus	0.0158	0.0245	CbGbCtD
Dabrafenib—CYP2C8—Hydrocortisone—systemic lupus erythematosus	0.0145	0.0224	CbGbCtD
Dabrafenib—CYP2C8—Cyclosporine—systemic lupus erythematosus	0.0137	0.0212	CbGbCtD
Dabrafenib—ABCG2—Methotrexate—systemic lupus erythematosus	0.0136	0.0211	CbGbCtD
Dabrafenib—ABCB1—Mycophenolate mofetil—systemic lupus erythematosus	0.0122	0.0189	CbGbCtD
Dabrafenib—SLC22A8—choroid plexus—systemic lupus erythematosus	0.0114	0.163	CbGeAlD
Dabrafenib—SLC22A6—Methotrexate—systemic lupus erythematosus	0.011	0.017	CbGbCtD
Dabrafenib—ABCB1—Betamethasone—systemic lupus erythematosus	0.0105	0.0162	CbGbCtD
Dabrafenib—ABCB1—Prednisolone—systemic lupus erythematosus	0.0103	0.016	CbGbCtD
Dabrafenib—ABCB1—Hydrocortisone—systemic lupus erythematosus	0.00979	0.0152	CbGbCtD
Dabrafenib—ABCB1—Prednisone—systemic lupus erythematosus	0.00975	0.0151	CbGbCtD
Dabrafenib—CYP3A4—Methylprednisolone—systemic lupus erythematosus	0.00964	0.015	CbGbCtD
Dabrafenib—ABCB1—Cyclosporine—systemic lupus erythematosus	0.00924	0.0143	CbGbCtD
Dabrafenib—CYP2C8—Dexamethasone—systemic lupus erythematosus	0.00899	0.014	CbGbCtD
Dabrafenib—CYP3A4—Dapsone—systemic lupus erythematosus	0.00843	0.0131	CbGbCtD
Dabrafenib—CYP3A4—Mycophenolate mofetil—systemic lupus erythematosus	0.00731	0.0113	CbGbCtD
Dabrafenib—CYP3A4—Triamcinolone—systemic lupus erythematosus	0.00731	0.0113	CbGbCtD
Dabrafenib—CYP3A4—Betamethasone—systemic lupus erythematosus	0.00627	0.00973	CbGbCtD
Dabrafenib—CYP3A4—Prednisolone—systemic lupus erythematosus	0.00619	0.0096	CbGbCtD
Dabrafenib—ABCB1—Dexamethasone—systemic lupus erythematosus	0.00609	0.00945	CbGbCtD
Dabrafenib—CYP3A4—Hydrocortisone—systemic lupus erythematosus	0.00587	0.0091	CbGbCtD
Dabrafenib—CYP3A4—Prednisone—systemic lupus erythematosus	0.00584	0.00907	CbGbCtD
Dabrafenib—CYP3A4—Cyclosporine—systemic lupus erythematosus	0.00554	0.0086	CbGbCtD
Dabrafenib—ABCB1—Methotrexate—systemic lupus erythematosus	0.00489	0.00759	CbGbCtD
Dabrafenib—CYP3A4—Dexamethasone—systemic lupus erythematosus	0.00365	0.00566	CbGbCtD
Dabrafenib—SLC22A8—urine—systemic lupus erythematosus	0.00304	0.0437	CbGeAlD
Dabrafenib—NEK11—lung—systemic lupus erythematosus	0.00297	0.0427	CbGeAlD
Dabrafenib—LIMK1—tendon—systemic lupus erythematosus	0.00243	0.0349	CbGeAlD
Dabrafenib—SLCO1B1—blood plasma—systemic lupus erythematosus	0.00204	0.0293	CbGeAlD
Dabrafenib—SIK1—connective tissue—systemic lupus erythematosus	0.00183	0.0262	CbGeAlD
Dabrafenib—SIK1—nephron tubule—systemic lupus erythematosus	0.00177	0.0254	CbGeAlD
Dabrafenib—SIK1—skin of body—systemic lupus erythematosus	0.00165	0.0237	CbGeAlD
Dabrafenib—SIK1—kidney—systemic lupus erythematosus	0.00155	0.0223	CbGeAlD
Dabrafenib—SIK1—cortex of kidney—systemic lupus erythematosus	0.00151	0.0217	CbGeAlD
Dabrafenib—CYP3A4—urine—systemic lupus erythematosus	0.00151	0.0217	CbGeAlD
Dabrafenib—BRAF—tendon—systemic lupus erythematosus	0.0015	0.0215	CbGeAlD
Dabrafenib—RAF1—connective tissue—systemic lupus erythematosus	0.00145	0.0209	CbGeAlD
Dabrafenib—BRAF—bone marrow—systemic lupus erythematosus	0.00145	0.0209	CbGeAlD
Dabrafenib—RAF1—nephron tubule—systemic lupus erythematosus	0.00141	0.0202	CbGeAlD
Dabrafenib—SLC22A6—nephron tubule—systemic lupus erythematosus	0.00137	0.0196	CbGeAlD
Dabrafenib—SIK1—lymphoid tissue—systemic lupus erythematosus	0.00133	0.0192	CbGeAlD
Dabrafenib—BRAF—lung—systemic lupus erythematosus	0.00132	0.0189	CbGeAlD
Dabrafenib—RAF1—skin of body—systemic lupus erythematosus	0.00131	0.0189	CbGeAlD
Dabrafenib—SIK1—tendon—systemic lupus erythematosus	0.00125	0.018	CbGeAlD
Dabrafenib—RAF1—kidney—systemic lupus erythematosus	0.00124	0.0178	CbGeAlD
Dabrafenib—SIK1—bone marrow—systemic lupus erythematosus	0.00122	0.0175	CbGeAlD
Dabrafenib—RAF1—cortex of kidney—systemic lupus erythematosus	0.0012	0.0173	CbGeAlD
Dabrafenib—SLC22A6—cortex of kidney—systemic lupus erythematosus	0.00117	0.0168	CbGeAlD
Dabrafenib—CYP2C8—blood plasma—systemic lupus erythematosus	0.00116	0.0167	CbGeAlD
Dabrafenib—SLCO1B3—lung—systemic lupus erythematosus	0.00113	0.0163	CbGeAlD
Dabrafenib—SIK1—lung—systemic lupus erythematosus	0.0011	0.0158	CbGeAlD
Dabrafenib—RAF1—lymphoid tissue—systemic lupus erythematosus	0.00106	0.0153	CbGeAlD
Dabrafenib—SIK1—nervous system—systemic lupus erythematosus	0.00102	0.0147	CbGeAlD
Dabrafenib—RAF1—tendon—systemic lupus erythematosus	0.000999	0.0143	CbGeAlD
Dabrafenib—SIK1—central nervous system—systemic lupus erythematosus	0.000982	0.0141	CbGeAlD
Dabrafenib—RAF1—bone marrow—systemic lupus erythematosus	0.000967	0.0139	CbGeAlD
Dabrafenib—SLCO1B1—kidney—systemic lupus erythematosus	0.000925	0.0133	CbGeAlD
Dabrafenib—RAF1—lung—systemic lupus erythematosus	0.000876	0.0126	CbGeAlD
Dabrafenib—SLC22A8—nephron tubule—systemic lupus erythematosus	0.000818	0.0118	CbGeAlD
Dabrafenib—RAF1—nervous system—systemic lupus erythematosus	0.000811	0.0117	CbGeAlD
Dabrafenib—CYP3A4—blood plasma—systemic lupus erythematosus	0.000786	0.0113	CbGeAlD
Dabrafenib—RAF1—central nervous system—systemic lupus erythematosus	0.000781	0.0112	CbGeAlD
Dabrafenib—SLC22A8—kidney—systemic lupus erythematosus	0.000719	0.0103	CbGeAlD
Dabrafenib—SLC22A8—cortex of kidney—systemic lupus erythematosus	0.0007	0.0101	CbGeAlD
Dabrafenib—ABCG2—nephron tubule—systemic lupus erythematosus	0.000582	0.00837	CbGeAlD
Dabrafenib—ABCB1—blood plasma—systemic lupus erythematosus	0.000557	0.008	CbGeAlD
Dabrafenib—CYP2C8—kidney—systemic lupus erythematosus	0.000526	0.00756	CbGeAlD
Dabrafenib—SLC22A8—nervous system—systemic lupus erythematosus	0.000472	0.00678	CbGeAlD
Dabrafenib—SLC22A8—central nervous system—systemic lupus erythematosus	0.000454	0.00653	CbGeAlD
Dabrafenib—ABCG2—bone marrow—systemic lupus erythematosus	0.0004	0.00575	CbGeAlD
Dabrafenib—ABCG2—lung—systemic lupus erythematosus	0.000362	0.00521	CbGeAlD
Dabrafenib—CYP3A4—kidney—systemic lupus erythematosus	0.000356	0.00512	CbGeAlD
Dabrafenib—ABCB1—nephron tubule—systemic lupus erythematosus	0.000287	0.00412	CbGeAlD
Dabrafenib—ABCB1—kidney—systemic lupus erythematosus	0.000252	0.00363	CbGeAlD
Dabrafenib—ABCB1—cortex of kidney—systemic lupus erythematosus	0.000246	0.00353	CbGeAlD
Dabrafenib—CYP3A4—nervous system—systemic lupus erythematosus	0.000234	0.00336	CbGeAlD
Dabrafenib—CYP3A4—central nervous system—systemic lupus erythematosus	0.000225	0.00324	CbGeAlD
Dabrafenib—ABCB1—lymphoid tissue—systemic lupus erythematosus	0.000217	0.00311	CbGeAlD
Dabrafenib—ABCB1—bone marrow—systemic lupus erythematosus	0.000197	0.00284	CbGeAlD
Dabrafenib—ABCB1—lung—systemic lupus erythematosus	0.000179	0.00257	CbGeAlD
Dabrafenib—ABCB1—nervous system—systemic lupus erythematosus	0.000166	0.00238	CbGeAlD
Dabrafenib—ABCB1—central nervous system—systemic lupus erythematosus	0.000159	0.00229	CbGeAlD
Dabrafenib—Nervous system disorder—Hydrocortisone—systemic lupus erythematosus	0.000132	0.000823	CcSEcCtD
Dabrafenib—Myalgia—Methylprednisolone—systemic lupus erythematosus	0.000132	0.000822	CcSEcCtD
Dabrafenib—Arthralgia—Methylprednisolone—systemic lupus erythematosus	0.000132	0.000822	CcSEcCtD
Dabrafenib—Eye disorder—Prednisone—systemic lupus erythematosus	0.000132	0.000821	CcSEcCtD
Dabrafenib—Decreased appetite—Cyclosporine—systemic lupus erythematosus	0.000132	0.000821	CcSEcCtD
Dabrafenib—Infestation NOS—Methotrexate—systemic lupus erythematosus	0.000131	0.000818	CcSEcCtD
Dabrafenib—Infestation—Methotrexate—systemic lupus erythematosus	0.000131	0.000818	CcSEcCtD
Dabrafenib—Rash—Azathioprine—systemic lupus erythematosus	0.000131	0.000817	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—systemic lupus erythematosus	0.000131	0.000816	CcSEcCtD
Dabrafenib—Dermatitis—Azathioprine—systemic lupus erythematosus	0.000131	0.000816	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Cyclosporine—systemic lupus erythematosus	0.000131	0.000815	CcSEcCtD
Dabrafenib—Skin disorder—Hydrocortisone—systemic lupus erythematosus	0.000131	0.000815	CcSEcCtD
Dabrafenib—Fatigue—Cyclosporine—systemic lupus erythematosus	0.000131	0.000814	CcSEcCtD
Dabrafenib—Headache—Azathioprine—systemic lupus erythematosus	0.00013	0.000811	CcSEcCtD
Dabrafenib—Hyperhidrosis—Hydrocortisone—systemic lupus erythematosus	0.00013	0.000811	CcSEcCtD
Dabrafenib—Dizziness—Leflunomide—systemic lupus erythematosus	0.00013	0.000809	CcSEcCtD
Dabrafenib—Constipation—Cyclosporine—systemic lupus erythematosus	0.000129	0.000807	CcSEcCtD
Dabrafenib—Dry mouth—Triamcinolone—systemic lupus erythematosus	0.000129	0.000806	CcSEcCtD
Dabrafenib—Renal failure—Methotrexate—systemic lupus erythematosus	0.000129	0.000804	CcSEcCtD
Dabrafenib—Decreased appetite—Mycophenolate mofetil—systemic lupus erythematosus	0.000128	0.0008	CcSEcCtD
Dabrafenib—Stomatitis—Methotrexate—systemic lupus erythematosus	0.000128	0.000797	CcSEcCtD
Dabrafenib—Angiopathy—Prednisone—systemic lupus erythematosus	0.000128	0.000797	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Mycophenolate mofetil—systemic lupus erythematosus	0.000127	0.000795	CcSEcCtD
Dabrafenib—Immune system disorder—Prednisone—systemic lupus erythematosus	0.000127	0.000794	CcSEcCtD
Dabrafenib—Oedema—Triamcinolone—systemic lupus erythematosus	0.000127	0.00079	CcSEcCtD
Dabrafenib—Constipation—Mycophenolate mofetil—systemic lupus erythematosus	0.000126	0.000787	CcSEcCtD
Dabrafenib—Arrhythmia—Prednisone—systemic lupus erythematosus	0.000126	0.000785	CcSEcCtD
Dabrafenib—Infection—Triamcinolone—systemic lupus erythematosus	0.000126	0.000785	CcSEcCtD
Dabrafenib—Hypotension—Hydrocortisone—systemic lupus erythematosus	0.000126	0.000784	CcSEcCtD
Dabrafenib—Infection—Methylprednisolone—systemic lupus erythematosus	0.000126	0.000783	CcSEcCtD
Dabrafenib—Haematuria—Methotrexate—systemic lupus erythematosus	0.000125	0.00078	CcSEcCtD
Dabrafenib—Vomiting—Leflunomide—systemic lupus erythematosus	0.000125	0.000778	CcSEcCtD
Dabrafenib—Insomnia—Prednisolone—systemic lupus erythematosus	0.000125	0.000777	CcSEcCtD
Dabrafenib—Alopecia—Prednisone—systemic lupus erythematosus	0.000125	0.000776	CcSEcCtD
Dabrafenib—Nervous system disorder—Methylprednisolone—systemic lupus erythematosus	0.000124	0.000773	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Cyclosporine—systemic lupus erythematosus	0.000124	0.000772	CcSEcCtD
Dabrafenib—Epistaxis—Methotrexate—systemic lupus erythematosus	0.000124	0.000771	CcSEcCtD
Dabrafenib—Rash—Leflunomide—systemic lupus erythematosus	0.000124	0.000771	CcSEcCtD
Dabrafenib—Dermatitis—Leflunomide—systemic lupus erythematosus	0.000124	0.00077	CcSEcCtD
Dabrafenib—Mental disorder—Prednisone—systemic lupus erythematosus	0.000123	0.00077	CcSEcCtD
Dabrafenib—Nausea—Azathioprine—systemic lupus erythematosus	0.000123	0.000769	CcSEcCtD
Dabrafenib—Headache—Leflunomide—systemic lupus erythematosus	0.000123	0.000766	CcSEcCtD
Dabrafenib—Skin disorder—Methylprednisolone—systemic lupus erythematosus	0.000123	0.000766	CcSEcCtD
Dabrafenib—Malnutrition—Prednisone—systemic lupus erythematosus	0.000123	0.000765	CcSEcCtD
Dabrafenib—Erythema—Prednisone—systemic lupus erythematosus	0.000123	0.000765	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Hydrocortisone—systemic lupus erythematosus	0.000123	0.000764	CcSEcCtD
Dabrafenib—Hyperhidrosis—Triamcinolone—systemic lupus erythematosus	0.000122	0.000764	CcSEcCtD
Dabrafenib—Hyperhidrosis—Methylprednisolone—systemic lupus erythematosus	0.000122	0.000762	CcSEcCtD
Dabrafenib—Insomnia—Hydrocortisone—systemic lupus erythematosus	0.000122	0.000759	CcSEcCtD
Dabrafenib—Hypertension—Dexamethasone—systemic lupus erythematosus	0.000122	0.000758	CcSEcCtD
Dabrafenib—Hypertension—Betamethasone—systemic lupus erythematosus	0.000122	0.000758	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Mycophenolate mofetil—systemic lupus erythematosus	0.000121	0.000753	CcSEcCtD
Dabrafenib—Myalgia—Betamethasone—systemic lupus erythematosus	0.00012	0.000748	CcSEcCtD
Dabrafenib—Myalgia—Dexamethasone—systemic lupus erythematosus	0.00012	0.000748	CcSEcCtD
Dabrafenib—Abdominal pain—Cyclosporine—systemic lupus erythematosus	0.00012	0.000746	CcSEcCtD
Dabrafenib—Body temperature increased—Cyclosporine—systemic lupus erythematosus	0.00012	0.000746	CcSEcCtD
Dabrafenib—Haemoglobin—Methotrexate—systemic lupus erythematosus	0.000118	0.000738	CcSEcCtD
Dabrafenib—Hypotension—Methylprednisolone—systemic lupus erythematosus	0.000118	0.000736	CcSEcCtD
Dabrafenib—Haemorrhage—Methotrexate—systemic lupus erythematosus	0.000118	0.000734	CcSEcCtD
Dabrafenib—Decreased appetite—Hydrocortisone—systemic lupus erythematosus	0.000117	0.000729	CcSEcCtD
Dabrafenib—Body temperature increased—Mycophenolate mofetil—systemic lupus erythematosus	0.000117	0.000728	CcSEcCtD
Dabrafenib—Abdominal pain—Mycophenolate mofetil—systemic lupus erythematosus	0.000117	0.000728	CcSEcCtD
Dabrafenib—Nausea—Leflunomide—systemic lupus erythematosus	0.000117	0.000726	CcSEcCtD
Dabrafenib—Urinary tract disorder—Methotrexate—systemic lupus erythematosus	0.000116	0.000725	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Hydrocortisone—systemic lupus erythematosus	0.000116	0.000724	CcSEcCtD
Dabrafenib—Fatigue—Hydrocortisone—systemic lupus erythematosus	0.000116	0.000723	CcSEcCtD
Dabrafenib—Vision blurred—Prednisone—systemic lupus erythematosus	0.000116	0.000721	CcSEcCtD
Dabrafenib—Urethral disorder—Methotrexate—systemic lupus erythematosus	0.000115	0.00072	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Triamcinolone—systemic lupus erythematosus	0.000115	0.00072	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Methylprednisolone—systemic lupus erythematosus	0.000115	0.000718	CcSEcCtD
Dabrafenib—Oedema—Dexamethasone—systemic lupus erythematosus	0.000115	0.000717	CcSEcCtD
Dabrafenib—Oedema—Betamethasone—systemic lupus erythematosus	0.000115	0.000717	CcSEcCtD
Dabrafenib—Insomnia—Triamcinolone—systemic lupus erythematosus	0.000115	0.000714	CcSEcCtD
Dabrafenib—Insomnia—Methylprednisolone—systemic lupus erythematosus	0.000114	0.000713	CcSEcCtD
Dabrafenib—Infection—Dexamethasone—systemic lupus erythematosus	0.000114	0.000712	CcSEcCtD
Dabrafenib—Infection—Betamethasone—systemic lupus erythematosus	0.000114	0.000712	CcSEcCtD
Dabrafenib—Anaemia—Prednisone—systemic lupus erythematosus	0.000113	0.000707	CcSEcCtD
Dabrafenib—Nervous system disorder—Betamethasone—systemic lupus erythematosus	0.000113	0.000703	CcSEcCtD
Dabrafenib—Nervous system disorder—Dexamethasone—systemic lupus erythematosus	0.000113	0.000703	CcSEcCtD
Dabrafenib—Thrombocytopenia—Betamethasone—systemic lupus erythematosus	0.000113	0.000702	CcSEcCtD
Dabrafenib—Thrombocytopenia—Dexamethasone—systemic lupus erythematosus	0.000113	0.000702	CcSEcCtD
Dabrafenib—Hypersensitivity—Cyclosporine—systemic lupus erythematosus	0.000112	0.000695	CcSEcCtD
Dabrafenib—Hyperhidrosis—Dexamethasone—systemic lupus erythematosus	0.000111	0.000693	CcSEcCtD
Dabrafenib—Hyperhidrosis—Betamethasone—systemic lupus erythematosus	0.000111	0.000693	CcSEcCtD
Dabrafenib—Eye disorder—Methotrexate—systemic lupus erythematosus	0.00011	0.000686	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Hydrocortisone—systemic lupus erythematosus	0.00011	0.000686	CcSEcCtD
Dabrafenib—Fatigue—Triamcinolone—systemic lupus erythematosus	0.000109	0.000681	CcSEcCtD
Dabrafenib—Fatigue—Methylprednisolone—systemic lupus erythematosus	0.000109	0.000679	CcSEcCtD
Dabrafenib—Hypersensitivity—Mycophenolate mofetil—systemic lupus erythematosus	0.000109	0.000678	CcSEcCtD
Dabrafenib—Asthenia—Cyclosporine—systemic lupus erythematosus	0.000109	0.000677	CcSEcCtD
Dabrafenib—Hypotension—Betamethasone—systemic lupus erythematosus	0.000107	0.00067	CcSEcCtD
Dabrafenib—Hypotension—Dexamethasone—systemic lupus erythematosus	0.000107	0.00067	CcSEcCtD
Dabrafenib—Pruritus—Cyclosporine—systemic lupus erythematosus	0.000107	0.000668	CcSEcCtD
Dabrafenib—Angiopathy—Methotrexate—systemic lupus erythematosus	0.000107	0.000666	CcSEcCtD
Dabrafenib—Immune system disorder—Methotrexate—systemic lupus erythematosus	0.000106	0.000663	CcSEcCtD
Dabrafenib—Abdominal pain—Hydrocortisone—systemic lupus erythematosus	0.000106	0.000663	CcSEcCtD
Dabrafenib—Body temperature increased—Hydrocortisone—systemic lupus erythematosus	0.000106	0.000663	CcSEcCtD
Dabrafenib—Mediastinal disorder—Methotrexate—systemic lupus erythematosus	0.000106	0.000662	CcSEcCtD
Dabrafenib—Asthenia—Mycophenolate mofetil—systemic lupus erythematosus	0.000106	0.000661	CcSEcCtD
Dabrafenib—Hypertension—Prednisone—systemic lupus erythematosus	0.000106	0.00066	CcSEcCtD
Dabrafenib—Chills—Methotrexate—systemic lupus erythematosus	0.000106	0.000659	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Dexamethasone—systemic lupus erythematosus	0.000105	0.000653	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Betamethasone—systemic lupus erythematosus	0.000105	0.000653	CcSEcCtD
Dabrafenib—Pruritus—Mycophenolate mofetil—systemic lupus erythematosus	0.000104	0.000651	CcSEcCtD
Dabrafenib—Arthralgia—Prednisone—systemic lupus erythematosus	0.000104	0.000651	CcSEcCtD
Dabrafenib—Myalgia—Prednisone—systemic lupus erythematosus	0.000104	0.000651	CcSEcCtD
Dabrafenib—Alopecia—Methotrexate—systemic lupus erythematosus	0.000104	0.000649	CcSEcCtD
Dabrafenib—Insomnia—Betamethasone—systemic lupus erythematosus	0.000104	0.000648	CcSEcCtD
Dabrafenib—Insomnia—Dexamethasone—systemic lupus erythematosus	0.000104	0.000648	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic lupus erythematosus	0.000104	0.000647	CcSEcCtD
Dabrafenib—Diarrhoea—Cyclosporine—systemic lupus erythematosus	0.000104	0.000646	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Methylprednisolone—systemic lupus erythematosus	0.000103	0.000644	CcSEcCtD
Dabrafenib—Mental disorder—Methotrexate—systemic lupus erythematosus	0.000103	0.000643	CcSEcCtD
Dabrafenib—Malnutrition—Methotrexate—systemic lupus erythematosus	0.000103	0.000639	CcSEcCtD
Dabrafenib—Erythema—Methotrexate—systemic lupus erythematosus	0.000103	0.000639	CcSEcCtD
Dabrafenib—Hypersensitivity—Prednisolone—systemic lupus erythematosus	0.000101	0.000633	CcSEcCtD
Dabrafenib—Diarrhoea—Mycophenolate mofetil—systemic lupus erythematosus	0.000101	0.00063	CcSEcCtD
Dabrafenib—Body temperature increased—Triamcinolone—systemic lupus erythematosus	0.0001	0.000624	CcSEcCtD
Dabrafenib—Dizziness—Cyclosporine—systemic lupus erythematosus	0.0001	0.000624	CcSEcCtD
Dabrafenib—Oedema—Prednisone—systemic lupus erythematosus	0.0001	0.000624	CcSEcCtD
Dabrafenib—Abdominal pain—Methylprednisolone—systemic lupus erythematosus	9.99e-05	0.000623	CcSEcCtD
Dabrafenib—Decreased appetite—Betamethasone—systemic lupus erythematosus	9.99e-05	0.000623	CcSEcCtD
Dabrafenib—Decreased appetite—Dexamethasone—systemic lupus erythematosus	9.99e-05	0.000623	CcSEcCtD
Dabrafenib—Infection—Prednisone—systemic lupus erythematosus	9.94e-05	0.00062	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Betamethasone—systemic lupus erythematosus	9.92e-05	0.000619	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Dexamethasone—systemic lupus erythematosus	9.92e-05	0.000619	CcSEcCtD
Dabrafenib—Back pain—Methotrexate—systemic lupus erythematosus	9.92e-05	0.000618	CcSEcCtD
Dabrafenib—Hypersensitivity—Hydrocortisone—systemic lupus erythematosus	9.91e-05	0.000618	CcSEcCtD
Dabrafenib—Fatigue—Betamethasone—systemic lupus erythematosus	9.91e-05	0.000618	CcSEcCtD
Dabrafenib—Fatigue—Dexamethasone—systemic lupus erythematosus	9.91e-05	0.000618	CcSEcCtD
Dabrafenib—Nervous system disorder—Prednisone—systemic lupus erythematosus	9.82e-05	0.000612	CcSEcCtD
Dabrafenib—Dizziness—Mycophenolate mofetil—systemic lupus erythematosus	9.77e-05	0.000609	CcSEcCtD
Dabrafenib—Skin disorder—Prednisone—systemic lupus erythematosus	9.72e-05	0.000606	CcSEcCtD
Dabrafenib—Hyperhidrosis—Prednisone—systemic lupus erythematosus	9.68e-05	0.000603	CcSEcCtD
Dabrafenib—Vision blurred—Methotrexate—systemic lupus erythematosus	9.66e-05	0.000602	CcSEcCtD
Dabrafenib—Asthenia—Hydrocortisone—systemic lupus erythematosus	9.65e-05	0.000602	CcSEcCtD
Dabrafenib—Vomiting—Cyclosporine—systemic lupus erythematosus	9.63e-05	0.0006	CcSEcCtD
Dabrafenib—Rash—Cyclosporine—systemic lupus erythematosus	9.54e-05	0.000595	CcSEcCtD
Dabrafenib—Dermatitis—Cyclosporine—systemic lupus erythematosus	9.54e-05	0.000595	CcSEcCtD
Dabrafenib—Pruritus—Hydrocortisone—systemic lupus erythematosus	9.52e-05	0.000594	CcSEcCtD
Dabrafenib—Headache—Cyclosporine—systemic lupus erythematosus	9.48e-05	0.000591	CcSEcCtD
Dabrafenib—Anaemia—Methotrexate—systemic lupus erythematosus	9.47e-05	0.000591	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Betamethasone—systemic lupus erythematosus	9.4e-05	0.000586	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Dexamethasone—systemic lupus erythematosus	9.4e-05	0.000586	CcSEcCtD
Dabrafenib—Vomiting—Mycophenolate mofetil—systemic lupus erythematosus	9.39e-05	0.000585	CcSEcCtD
Dabrafenib—Hypersensitivity—Triamcinolone—systemic lupus erythematosus	9.33e-05	0.000582	CcSEcCtD
Dabrafenib—Hypersensitivity—Methylprednisolone—systemic lupus erythematosus	9.31e-05	0.000581	CcSEcCtD
Dabrafenib—Rash—Mycophenolate mofetil—systemic lupus erythematosus	9.31e-05	0.000581	CcSEcCtD
Dabrafenib—Dermatitis—Mycophenolate mofetil—systemic lupus erythematosus	9.3e-05	0.00058	CcSEcCtD
Dabrafenib—Headache—Mycophenolate mofetil—systemic lupus erythematosus	9.25e-05	0.000577	CcSEcCtD
Dabrafenib—Diarrhoea—Hydrocortisone—systemic lupus erythematosus	9.21e-05	0.000574	CcSEcCtD
Dabrafenib—Leukopenia—Methotrexate—systemic lupus erythematosus	9.18e-05	0.000572	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Prednisone—systemic lupus erythematosus	9.12e-05	0.000569	CcSEcCtD
Dabrafenib—Dizziness—Prednisolone—systemic lupus erythematosus	9.11e-05	0.000568	CcSEcCtD
Dabrafenib—Asthenia—Triamcinolone—systemic lupus erythematosus	9.09e-05	0.000567	CcSEcCtD
Dabrafenib—Body temperature increased—Betamethasone—systemic lupus erythematosus	9.09e-05	0.000567	CcSEcCtD
Dabrafenib—Abdominal pain—Dexamethasone—systemic lupus erythematosus	9.09e-05	0.000567	CcSEcCtD
Dabrafenib—Abdominal pain—Betamethasone—systemic lupus erythematosus	9.09e-05	0.000567	CcSEcCtD
Dabrafenib—Body temperature increased—Dexamethasone—systemic lupus erythematosus	9.09e-05	0.000567	CcSEcCtD
Dabrafenib—Asthenia—Methylprednisolone—systemic lupus erythematosus	9.07e-05	0.000565	CcSEcCtD
Dabrafenib—Insomnia—Prednisone—systemic lupus erythematosus	9.05e-05	0.000565	CcSEcCtD
Dabrafenib—Nausea—Cyclosporine—systemic lupus erythematosus	8.99e-05	0.000561	CcSEcCtD
Dabrafenib—Pruritus—Triamcinolone—systemic lupus erythematosus	8.96e-05	0.000559	CcSEcCtD
Dabrafenib—Cough—Methotrexate—systemic lupus erythematosus	8.94e-05	0.000558	CcSEcCtD
Dabrafenib—Pruritus—Methylprednisolone—systemic lupus erythematosus	8.94e-05	0.000558	CcSEcCtD
Dabrafenib—Dizziness—Hydrocortisone—systemic lupus erythematosus	8.9e-05	0.000555	CcSEcCtD
Dabrafenib—Nausea—Mycophenolate mofetil—systemic lupus erythematosus	8.77e-05	0.000547	CcSEcCtD
Dabrafenib—Arthralgia—Methotrexate—systemic lupus erythematosus	8.73e-05	0.000544	CcSEcCtD
Dabrafenib—Myalgia—Methotrexate—systemic lupus erythematosus	8.73e-05	0.000544	CcSEcCtD
Dabrafenib—Decreased appetite—Prednisone—systemic lupus erythematosus	8.7e-05	0.000543	CcSEcCtD
Dabrafenib—Rash—Prednisolone—systemic lupus erythematosus	8.69e-05	0.000542	CcSEcCtD
Dabrafenib—Dermatitis—Prednisolone—systemic lupus erythematosus	8.68e-05	0.000541	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic lupus erythematosus	8.67e-05	0.00054	CcSEcCtD
Dabrafenib—Diarrhoea—Methylprednisolone—systemic lupus erythematosus	8.65e-05	0.000539	CcSEcCtD
Dabrafenib—Fatigue—Prednisone—systemic lupus erythematosus	8.63e-05	0.000538	CcSEcCtD
Dabrafenib—Headache—Prednisolone—systemic lupus erythematosus	8.63e-05	0.000538	CcSEcCtD
Dabrafenib—Constipation—Prednisone—systemic lupus erythematosus	8.56e-05	0.000534	CcSEcCtD
Dabrafenib—Vomiting—Hydrocortisone—systemic lupus erythematosus	8.55e-05	0.000533	CcSEcCtD
Dabrafenib—Rash—Hydrocortisone—systemic lupus erythematosus	8.48e-05	0.000529	CcSEcCtD
Dabrafenib—Dermatitis—Hydrocortisone—systemic lupus erythematosus	8.48e-05	0.000528	CcSEcCtD
Dabrafenib—Headache—Hydrocortisone—systemic lupus erythematosus	8.43e-05	0.000526	CcSEcCtD
Dabrafenib—Dizziness—Triamcinolone—systemic lupus erythematosus	8.38e-05	0.000522	CcSEcCtD
Dabrafenib—Dizziness—Methylprednisolone—systemic lupus erythematosus	8.36e-05	0.000521	CcSEcCtD
Dabrafenib—Infection—Methotrexate—systemic lupus erythematosus	8.31e-05	0.000518	CcSEcCtD
Dabrafenib—Asthenia—Dexamethasone—systemic lupus erythematosus	8.25e-05	0.000514	CcSEcCtD
Dabrafenib—Asthenia—Betamethasone—systemic lupus erythematosus	8.25e-05	0.000514	CcSEcCtD
Dabrafenib—Nervous system disorder—Methotrexate—systemic lupus erythematosus	8.2e-05	0.000512	CcSEcCtD
Dabrafenib—Thrombocytopenia—Methotrexate—systemic lupus erythematosus	8.19e-05	0.000511	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Prednisone—systemic lupus erythematosus	8.19e-05	0.00051	CcSEcCtD
Dabrafenib—Nausea—Prednisolone—systemic lupus erythematosus	8.18e-05	0.00051	CcSEcCtD
Dabrafenib—Pruritus—Betamethasone—systemic lupus erythematosus	8.13e-05	0.000507	CcSEcCtD
Dabrafenib—Pruritus—Dexamethasone—systemic lupus erythematosus	8.13e-05	0.000507	CcSEcCtD
Dabrafenib—Skin disorder—Methotrexate—systemic lupus erythematosus	8.13e-05	0.000507	CcSEcCtD
Dabrafenib—Hyperhidrosis—Methotrexate—systemic lupus erythematosus	8.09e-05	0.000504	CcSEcCtD
Dabrafenib—Vomiting—Triamcinolone—systemic lupus erythematosus	8.05e-05	0.000502	CcSEcCtD
Dabrafenib—Vomiting—Methylprednisolone—systemic lupus erythematosus	8.04e-05	0.000501	CcSEcCtD
Dabrafenib—Nausea—Hydrocortisone—systemic lupus erythematosus	7.99e-05	0.000498	CcSEcCtD
Dabrafenib—Rash—Triamcinolone—systemic lupus erythematosus	7.99e-05	0.000498	CcSEcCtD
Dabrafenib—Dermatitis—Triamcinolone—systemic lupus erythematosus	7.98e-05	0.000498	CcSEcCtD
Dabrafenib—Rash—Methylprednisolone—systemic lupus erythematosus	7.97e-05	0.000497	CcSEcCtD
Dabrafenib—Dermatitis—Methylprednisolone—systemic lupus erythematosus	7.96e-05	0.000496	CcSEcCtD
Dabrafenib—Headache—Triamcinolone—systemic lupus erythematosus	7.94e-05	0.000495	CcSEcCtD
Dabrafenib—Headache—Methylprednisolone—systemic lupus erythematosus	7.92e-05	0.000494	CcSEcCtD
Dabrafenib—Body temperature increased—Prednisone—systemic lupus erythematosus	7.91e-05	0.000493	CcSEcCtD
Dabrafenib—Abdominal pain—Prednisone—systemic lupus erythematosus	7.91e-05	0.000493	CcSEcCtD
Dabrafenib—Diarrhoea—Dexamethasone—systemic lupus erythematosus	7.86e-05	0.00049	CcSEcCtD
Dabrafenib—Diarrhoea—Betamethasone—systemic lupus erythematosus	7.86e-05	0.00049	CcSEcCtD
Dabrafenib—Hypotension—Methotrexate—systemic lupus erythematosus	7.82e-05	0.000487	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Methotrexate—systemic lupus erythematosus	7.62e-05	0.000475	CcSEcCtD
Dabrafenib—Dizziness—Betamethasone—systemic lupus erythematosus	7.6e-05	0.000474	CcSEcCtD
Dabrafenib—Dizziness—Dexamethasone—systemic lupus erythematosus	7.6e-05	0.000474	CcSEcCtD
Dabrafenib—Insomnia—Methotrexate—systemic lupus erythematosus	7.57e-05	0.000472	CcSEcCtD
Dabrafenib—Nausea—Triamcinolone—systemic lupus erythematosus	7.52e-05	0.000469	CcSEcCtD
Dabrafenib—Nausea—Methylprednisolone—systemic lupus erythematosus	7.51e-05	0.000468	CcSEcCtD
Dabrafenib—Hypersensitivity—Prednisone—systemic lupus erythematosus	7.38e-05	0.00046	CcSEcCtD
Dabrafenib—Vomiting—Dexamethasone—systemic lupus erythematosus	7.31e-05	0.000456	CcSEcCtD
Dabrafenib—Vomiting—Betamethasone—systemic lupus erythematosus	7.31e-05	0.000456	CcSEcCtD
Dabrafenib—Decreased appetite—Methotrexate—systemic lupus erythematosus	7.27e-05	0.000453	CcSEcCtD
Dabrafenib—Rash—Betamethasone—systemic lupus erythematosus	7.25e-05	0.000452	CcSEcCtD
Dabrafenib—Rash—Dexamethasone—systemic lupus erythematosus	7.25e-05	0.000452	CcSEcCtD
Dabrafenib—Dermatitis—Dexamethasone—systemic lupus erythematosus	7.24e-05	0.000451	CcSEcCtD
Dabrafenib—Dermatitis—Betamethasone—systemic lupus erythematosus	7.24e-05	0.000451	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Methotrexate—systemic lupus erythematosus	7.22e-05	0.00045	CcSEcCtD
Dabrafenib—Fatigue—Methotrexate—systemic lupus erythematosus	7.21e-05	0.00045	CcSEcCtD
Dabrafenib—Headache—Betamethasone—systemic lupus erythematosus	7.2e-05	0.000449	CcSEcCtD
Dabrafenib—Headache—Dexamethasone—systemic lupus erythematosus	7.2e-05	0.000449	CcSEcCtD
Dabrafenib—Asthenia—Prednisone—systemic lupus erythematosus	7.18e-05	0.000448	CcSEcCtD
Dabrafenib—Pruritus—Prednisone—systemic lupus erythematosus	7.08e-05	0.000442	CcSEcCtD
Dabrafenib—Diarrhoea—Prednisone—systemic lupus erythematosus	6.85e-05	0.000427	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Methotrexate—systemic lupus erythematosus	6.84e-05	0.000427	CcSEcCtD
Dabrafenib—Nausea—Betamethasone—systemic lupus erythematosus	6.83e-05	0.000426	CcSEcCtD
Dabrafenib—Nausea—Dexamethasone—systemic lupus erythematosus	6.83e-05	0.000426	CcSEcCtD
Dabrafenib—Dizziness—Prednisone—systemic lupus erythematosus	6.62e-05	0.000413	CcSEcCtD
Dabrafenib—Abdominal pain—Methotrexate—systemic lupus erythematosus	6.61e-05	0.000412	CcSEcCtD
Dabrafenib—Body temperature increased—Methotrexate—systemic lupus erythematosus	6.61e-05	0.000412	CcSEcCtD
Dabrafenib—Vomiting—Prednisone—systemic lupus erythematosus	6.36e-05	0.000397	CcSEcCtD
Dabrafenib—Rash—Prednisone—systemic lupus erythematosus	6.31e-05	0.000394	CcSEcCtD
Dabrafenib—Dermatitis—Prednisone—systemic lupus erythematosus	6.31e-05	0.000393	CcSEcCtD
Dabrafenib—Headache—Prednisone—systemic lupus erythematosus	6.27e-05	0.000391	CcSEcCtD
Dabrafenib—Hypersensitivity—Methotrexate—systemic lupus erythematosus	6.16e-05	0.000384	CcSEcCtD
Dabrafenib—Asthenia—Methotrexate—systemic lupus erythematosus	6e-05	0.000374	CcSEcCtD
Dabrafenib—Nausea—Prednisone—systemic lupus erythematosus	5.95e-05	0.000371	CcSEcCtD
Dabrafenib—Pruritus—Methotrexate—systemic lupus erythematosus	5.92e-05	0.000369	CcSEcCtD
Dabrafenib—Diarrhoea—Methotrexate—systemic lupus erythematosus	5.72e-05	0.000357	CcSEcCtD
Dabrafenib—Dizziness—Methotrexate—systemic lupus erythematosus	5.53e-05	0.000345	CcSEcCtD
Dabrafenib—Vomiting—Methotrexate—systemic lupus erythematosus	5.32e-05	0.000332	CcSEcCtD
Dabrafenib—Rash—Methotrexate—systemic lupus erythematosus	5.27e-05	0.000329	CcSEcCtD
Dabrafenib—Dermatitis—Methotrexate—systemic lupus erythematosus	5.27e-05	0.000329	CcSEcCtD
Dabrafenib—Headache—Methotrexate—systemic lupus erythematosus	5.24e-05	0.000327	CcSEcCtD
Dabrafenib—Nausea—Methotrexate—systemic lupus erythematosus	4.97e-05	0.00031	CcSEcCtD
Dabrafenib—RAF1—Immune System—BLK—systemic lupus erythematosus	2.49e-05	0.000198	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism of lipids and lipoproteins—ALB—systemic lupus erythematosus	2.49e-05	0.000198	CbGpPWpGaD
Dabrafenib—RAF1—Disease—CD247—systemic lupus erythematosus	2.49e-05	0.000198	CbGpPWpGaD
Dabrafenib—RAF1—Downstream signaling of activated FGFR—IL6—systemic lupus erythematosus	2.47e-05	0.000197	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—CDKN1B—systemic lupus erythematosus	2.45e-05	0.000195	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—NCF2—systemic lupus erythematosus	2.45e-05	0.000195	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by ERBB4—IL6—systemic lupus erythematosus	2.43e-05	0.000194	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—LYN—systemic lupus erythematosus	2.43e-05	0.000193	CbGpPWpGaD
Dabrafenib—LIMK1—Innate Immune System—IL6—systemic lupus erythematosus	2.42e-05	0.000192	CbGpPWpGaD
Dabrafenib—RAF1—Disease—NCF2—systemic lupus erythematosus	2.42e-05	0.000192	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—C3—systemic lupus erythematosus	2.41e-05	0.000192	CbGpPWpGaD
Dabrafenib—ABCB1—Allograft Rejection—TNF—systemic lupus erythematosus	2.4e-05	0.000191	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—IL2—systemic lupus erythematosus	2.4e-05	0.000191	CbGpPWpGaD
Dabrafenib—RAF1—Platelet activation, signaling and aggregation—TGFB1—systemic lupus erythematosus	2.39e-05	0.00019	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—SH2B3—systemic lupus erythematosus	2.39e-05	0.00019	CbGpPWpGaD
Dabrafenib—SLCO1B3—Transmembrane transport of small molecules—ALB—systemic lupus erythematosus	2.37e-05	0.000188	CbGpPWpGaD
Dabrafenib—CYP3A4—Biological oxidations—RXRA—systemic lupus erythematosus	2.37e-05	0.000188	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by NGF—CDKN1A—systemic lupus erythematosus	2.35e-05	0.000187	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—F2—systemic lupus erythematosus	2.35e-05	0.000187	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—NAT2—systemic lupus erythematosus	2.34e-05	0.000186	CbGpPWpGaD
Dabrafenib—RAF1—Downstream signal transduction—IL6—systemic lupus erythematosus	2.32e-05	0.000185	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—C3—systemic lupus erythematosus	2.31e-05	0.000184	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by FGFR—IL6—systemic lupus erythematosus	2.31e-05	0.000184	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by ERBB2—IL6—systemic lupus erythematosus	2.3e-05	0.000183	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—CXCL12—systemic lupus erythematosus	2.29e-05	0.000182	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—CRP—systemic lupus erythematosus	2.29e-05	0.000182	CbGpPWpGaD
Dabrafenib—RAF1—DAP12 signaling—IL6—systemic lupus erythematosus	2.29e-05	0.000182	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—CDKN1A—systemic lupus erythematosus	2.26e-05	0.00018	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—PTPRC—systemic lupus erythematosus	2.23e-05	0.000177	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—IL1RN—systemic lupus erythematosus	2.22e-05	0.000176	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—PPARG—systemic lupus erythematosus	2.21e-05	0.000176	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—TLR4—systemic lupus erythematosus	2.2e-05	0.000175	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism of lipids and lipoproteins—PTGS2—systemic lupus erythematosus	2.18e-05	0.000173	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—NAT2—systemic lupus erythematosus	2.17e-05	0.000172	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by FGFR in disease—IL6—systemic lupus erythematosus	2.15e-05	0.000171	CbGpPWpGaD
Dabrafenib—RAF1—DAP12 interactions—IL6—systemic lupus erythematosus	2.15e-05	0.000171	CbGpPWpGaD
Dabrafenib—RAF1—Fc epsilon receptor (FCERI) signaling—IL6—systemic lupus erythematosus	2.15e-05	0.000171	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—EP300—systemic lupus erythematosus	2.15e-05	0.000171	CbGpPWpGaD
Dabrafenib—RAF1—Axon guidance—MMP9—systemic lupus erythematosus	2.14e-05	0.00017	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—RASGRP1—systemic lupus erythematosus	2.14e-05	0.00017	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by EGFR—IL6—systemic lupus erythematosus	2.13e-05	0.00017	CbGpPWpGaD
Dabrafenib—BRAF—Signaling by NGF—IL6—systemic lupus erythematosus	2.12e-05	0.000169	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by EGFR in Cancer—IL6—systemic lupus erythematosus	2.12e-05	0.000168	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—HLA-DRB1—systemic lupus erythematosus	2.11e-05	0.000168	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by PDGF—IL6—systemic lupus erythematosus	2.11e-05	0.000168	CbGpPWpGaD
Dabrafenib—SLC22A8—Transmembrane transport of small molecules—ALB—systemic lupus erythematosus	2.09e-05	0.000167	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—TLR9—systemic lupus erythematosus	2.08e-05	0.000165	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—CD40—systemic lupus erythematosus	2.07e-05	0.000165	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—CTLA4—systemic lupus erythematosus	2.04e-05	0.000162	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—HMGB1—systemic lupus erythematosus	2.04e-05	0.000162	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—CD80—systemic lupus erythematosus	2.03e-05	0.000161	CbGpPWpGaD
Dabrafenib—BRAF—Disease—JAK1—systemic lupus erythematosus	2.02e-05	0.000161	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—P2RY12—systemic lupus erythematosus	2.01e-05	0.00016	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—IFNA1—systemic lupus erythematosus	2.01e-05	0.00016	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CXCL12—systemic lupus erythematosus	1.96e-05	0.000156	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—RASGRP1—systemic lupus erythematosus	1.95e-05	0.000155	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—RXRA—systemic lupus erythematosus	1.95e-05	0.000155	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—ALB—systemic lupus erythematosus	1.95e-05	0.000155	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—CD79A—systemic lupus erythematosus	1.95e-05	0.000155	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—CD80—systemic lupus erythematosus	1.95e-05	0.000155	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—TYK2—systemic lupus erythematosus	1.94e-05	0.000154	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—JUNB—systemic lupus erythematosus	1.92e-05	0.000153	CbGpPWpGaD
Dabrafenib—RAF1—Axon guidance—VEGFA—systemic lupus erythematosus	1.92e-05	0.000153	CbGpPWpGaD
Dabrafenib—BRAF—Disease—CCR5—systemic lupus erythematosus	1.91e-05	0.000152	CbGpPWpGaD
Dabrafenib—RAF1—NGF signalling via TRKA from the plasma membrane—IL6—systemic lupus erythematosus	1.91e-05	0.000152	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—HIST2H2AC—systemic lupus erythematosus	1.9e-05	0.000151	CbGpPWpGaD
Dabrafenib—RAF1—Disease—JUNB—systemic lupus erythematosus	1.9e-05	0.000151	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—PRL—systemic lupus erythematosus	1.89e-05	0.000151	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—NOS3—systemic lupus erythematosus	1.87e-05	0.000148	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism of lipids and lipoproteins—PPARG—systemic lupus erythematosus	1.86e-05	0.000148	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CSK—systemic lupus erythematosus	1.85e-05	0.000147	CbGpPWpGaD
Dabrafenib—RAF1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—systemic lupus erythematosus	1.84e-05	0.000147	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—RASGRP1—systemic lupus erythematosus	1.82e-05	0.000145	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism of lipids and lipoproteins—EP300—systemic lupus erythematosus	1.81e-05	0.000144	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—HLA-DQA1—systemic lupus erythematosus	1.8e-05	0.000143	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—PRL—systemic lupus erythematosus	1.77e-05	0.000141	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—systemic lupus erythematosus	1.75e-05	0.00014	CbGpPWpGaD
Dabrafenib—RAF1—Disease—PRL—systemic lupus erythematosus	1.75e-05	0.000139	CbGpPWpGaD
Dabrafenib—SLC22A6—Transmembrane transport of small molecules—ALB—systemic lupus erythematosus	1.75e-05	0.000139	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—TYK2—systemic lupus erythematosus	1.71e-05	0.000136	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—NCF2—systemic lupus erythematosus	1.69e-05	0.000135	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—RXRA—systemic lupus erythematosus	1.69e-05	0.000135	CbGpPWpGaD
Dabrafenib—RAF1—Transmembrane transport of small molecules—ALB—systemic lupus erythematosus	1.69e-05	0.000134	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—LYN—systemic lupus erythematosus	1.68e-05	0.000134	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—HLA-DQB1—systemic lupus erythematosus	1.68e-05	0.000134	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism of lipids and lipoproteins—ALB—systemic lupus erythematosus	1.67e-05	0.000133	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1B—systemic lupus erythematosus	1.66e-05	0.000132	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—JAK1—systemic lupus erythematosus	1.66e-05	0.000132	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—SH2B3—systemic lupus erythematosus	1.65e-05	0.000131	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—IL18—systemic lupus erythematosus	1.59e-05	0.000127	CbGpPWpGaD
Dabrafenib—SLCO1B1—Transmembrane transport of small molecules—ALB—systemic lupus erythematosus	1.59e-05	0.000127	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—CD40LG—systemic lupus erythematosus	1.59e-05	0.000126	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—IL2—systemic lupus erythematosus	1.58e-05	0.000126	CbGpPWpGaD
Dabrafenib—BRAF—Disease—CD80—systemic lupus erythematosus	1.58e-05	0.000125	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—CCR5—systemic lupus erythematosus	1.57e-05	0.000125	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—CD8A—systemic lupus erythematosus	1.57e-05	0.000125	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—IL2RA—systemic lupus erythematosus	1.55e-05	0.000123	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—CD4—systemic lupus erythematosus	1.55e-05	0.000123	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—C3—systemic lupus erythematosus	1.53e-05	0.000122	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—systemic lupus erythematosus	1.53e-05	0.000122	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—MMP9—systemic lupus erythematosus	1.53e-05	0.000121	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—JAK1—systemic lupus erythematosus	1.51e-05	0.00012	CbGpPWpGaD
Dabrafenib—RAF1—Cytokine Signaling in Immune system—IL6—systemic lupus erythematosus	1.49e-05	0.000119	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—CD4—systemic lupus erythematosus	1.49e-05	0.000118	CbGpPWpGaD
Dabrafenib—ABCG2—Transmembrane transport of small molecules—ALB—systemic lupus erythematosus	1.47e-05	0.000117	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by NGF—IL6—systemic lupus erythematosus	1.47e-05	0.000117	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism of lipids and lipoproteins—PTGS2—systemic lupus erythematosus	1.46e-05	0.000116	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—systemic lupus erythematosus	1.46e-05	0.000116	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—CDKN1B—systemic lupus erythematosus	1.45e-05	0.000116	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—EP300—systemic lupus erythematosus	1.45e-05	0.000115	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—EP300—systemic lupus erythematosus	1.42e-05	0.000113	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—JAK1—systemic lupus erythematosus	1.42e-05	0.000113	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—IL2RA—systemic lupus erythematosus	1.41e-05	0.000113	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—IL6—systemic lupus erythematosus	1.41e-05	0.000112	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—C3—systemic lupus erythematosus	1.4e-05	0.000112	CbGpPWpGaD
Dabrafenib—ABCB1—Transmembrane transport of small molecules—RXRA—systemic lupus erythematosus	1.4e-05	0.000112	CbGpPWpGaD
Dabrafenib—RAF1—Disease—JAK1—systemic lupus erythematosus	1.4e-05	0.000111	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—CDKN1B—systemic lupus erythematosus	1.4e-05	0.000111	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—systemic lupus erythematosus	1.38e-05	0.00011	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—VEGFA—systemic lupus erythematosus	1.37e-05	0.000109	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CXCL12—systemic lupus erythematosus	1.35e-05	0.000108	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—F2—systemic lupus erythematosus	1.35e-05	0.000107	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—NAT2—systemic lupus erythematosus	1.34e-05	0.000107	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—VEGFA—systemic lupus erythematosus	1.34e-05	0.000107	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—CDKN1A—systemic lupus erythematosus	1.34e-05	0.000107	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CCR5—systemic lupus erythematosus	1.34e-05	0.000107	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—CRP—systemic lupus erythematosus	1.33e-05	0.000106	CbGpPWpGaD
Dabrafenib—BRAF—Disease—TYK2—systemic lupus erythematosus	1.33e-05	0.000106	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—JUNB—systemic lupus erythematosus	1.33e-05	0.000106	CbGpPWpGaD
Dabrafenib—RAF1—Axon guidance—IL6—systemic lupus erythematosus	1.33e-05	0.000106	CbGpPWpGaD
Dabrafenib—RAF1—Disease—CCR5—systemic lupus erythematosus	1.32e-05	0.000105	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—IL2RA—systemic lupus erythematosus	1.32e-05	0.000105	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—RXRA—systemic lupus erythematosus	1.31e-05	0.000104	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—C3—systemic lupus erythematosus	1.31e-05	0.000104	CbGpPWpGaD
Dabrafenib—BRAF—Disease—NOS3—systemic lupus erythematosus	1.31e-05	0.000104	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—CDKN1A—systemic lupus erythematosus	1.29e-05	0.000103	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—TLR4—systemic lupus erythematosus	1.28e-05	0.000102	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—HLA-DRB1—systemic lupus erythematosus	1.28e-05	0.000102	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—EP300—systemic lupus erythematosus	1.28e-05	0.000102	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—systemic lupus erythematosus	1.27e-05	0.000101	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—RASGRP1—systemic lupus erythematosus	1.26e-05	0.0001	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—TGFB1—systemic lupus erythematosus	1.26e-05	0.0001	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—TGFB1—systemic lupus erythematosus	1.23e-05	9.81e-05	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—PPARG—systemic lupus erythematosus	1.23e-05	9.81e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—PRL—systemic lupus erythematosus	1.22e-05	9.74e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism of lipids and lipoproteins—EP300—systemic lupus erythematosus	1.22e-05	9.68e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—RXRA—systemic lupus erythematosus	1.21e-05	9.66e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—CD4—systemic lupus erythematosus	1.2e-05	9.57e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—CCL2—systemic lupus erythematosus	1.2e-05	9.56e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—PTGS2—systemic lupus erythematosus	1.19e-05	9.5e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—systemic lupus erythematosus	1.18e-05	9.42e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—CD80—systemic lupus erythematosus	1.18e-05	9.39e-05	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—TNF—systemic lupus erythematosus	1.17e-05	9.34e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—NAT2—systemic lupus erythematosus	1.17e-05	9.32e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—F2—systemic lupus erythematosus	1.15e-05	9.15e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—CDKN1B—systemic lupus erythematosus	1.13e-05	9e-05	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—ALB—systemic lupus erythematosus	1.11e-05	8.82e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CD80—systemic lupus erythematosus	1.1e-05	8.78e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—TYK2—systemic lupus erythematosus	1.09e-05	8.68e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—CD80—systemic lupus erythematosus	1.09e-05	8.67e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—systemic lupus erythematosus	1.07e-05	8.5e-05	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—NOS3—systemic lupus erythematosus	1.06e-05	8.44e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—CDKN1A—systemic lupus erythematosus	1.04e-05	8.3e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CCL2—systemic lupus erythematosus	1.03e-05	8.16e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—TYK2—systemic lupus erythematosus	9.96e-06	7.93e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—EP300—systemic lupus erythematosus	9.93e-06	7.9e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—JAK1—systemic lupus erythematosus	9.79e-06	7.79e-05	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—PTGS2—systemic lupus erythematosus	9.7e-06	7.72e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—ALB—systemic lupus erythematosus	9.61e-06	7.65e-05	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—IL6—systemic lupus erythematosus	9.47e-06	7.54e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—IFNG—systemic lupus erythematosus	9.33e-06	7.42e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—TYK2—systemic lupus erythematosus	9.31e-06	7.41e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CCR5—systemic lupus erythematosus	9.28e-06	7.38e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—TYK2—systemic lupus erythematosus	9.2e-06	7.32e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—IL2RA—systemic lupus erythematosus	9.14e-06	7.28e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—NOS3—systemic lupus erythematosus	9.14e-06	7.27e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—IL2—systemic lupus erythematosus	9.07e-06	7.22e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—C3—systemic lupus erythematosus	9.07e-06	7.21e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—NOS3—systemic lupus erythematosus	9.03e-06	7.18e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—CD4—systemic lupus erythematosus	9.01e-06	7.17e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—TGFB1—systemic lupus erythematosus	8.63e-06	6.87e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—CDKN1B—systemic lupus erythematosus	8.47e-06	6.74e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—systemic lupus erythematosus	8.41e-06	6.69e-05	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—IL6—systemic lupus erythematosus	8.37e-06	6.66e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—CD4—systemic lupus erythematosus	8.32e-06	6.62e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—IL2—systemic lupus erythematosus	8.29e-06	6.6e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—PPARG—systemic lupus erythematosus	8.28e-06	6.59e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—PTGS2—systemic lupus erythematosus	8.26e-06	6.57e-05	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—EP300—systemic lupus erythematosus	8.07e-06	6.42e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Transmembrane transport of small molecules—ALB—systemic lupus erythematosus	7.96e-06	6.33e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—F2—systemic lupus erythematosus	7.96e-06	6.33e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CDKN1B—systemic lupus erythematosus	7.92e-06	6.3e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—CDKN1B—systemic lupus erythematosus	7.82e-06	6.22e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—CDKN1A—systemic lupus erythematosus	7.82e-06	6.22e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—IL2—systemic lupus erythematosus	7.75e-06	6.16e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—PPARG—systemic lupus erythematosus	7.67e-06	6.1e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CD80—systemic lupus erythematosus	7.63e-06	6.07e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—RXRA—systemic lupus erythematosus	7.54e-06	6e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—ALB—systemic lupus erythematosus	7.45e-06	5.93e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—EP300—systemic lupus erythematosus	7.44e-06	5.92e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—MMP9—systemic lupus erythematosus	7.33e-06	5.83e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CDKN1A—systemic lupus erythematosus	7.31e-06	5.81e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—CDKN1A—systemic lupus erythematosus	7.22e-06	5.74e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—NAT2—systemic lupus erythematosus	7.22e-06	5.74e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—NOS3—systemic lupus erythematosus	7.12e-06	5.67e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CCL2—systemic lupus erythematosus	7.09e-06	5.65e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—EP300—systemic lupus erythematosus	6.99e-06	5.56e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—EP300—systemic lupus erythematosus	6.95e-06	5.53e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—ALB—systemic lupus erythematosus	6.9e-06	5.49e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—EP300—systemic lupus erythematosus	6.87e-06	5.47e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—NOS3—systemic lupus erythematosus	6.6e-06	5.25e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—VEGFA—systemic lupus erythematosus	6.58e-06	5.24e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—RXRA—systemic lupus erythematosus	6.57e-06	5.23e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—PTGS2—systemic lupus erythematosus	6.52e-06	5.18e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—IL6—systemic lupus erythematosus	6.5e-06	5.17e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—TYK2—systemic lupus erythematosus	6.44e-06	5.13e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—NOS3—systemic lupus erythematosus	6.32e-06	5.03e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—TGFB1—systemic lupus erythematosus	6.04e-06	4.81e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—PTGS2—systemic lupus erythematosus	6.03e-06	4.8e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—TGFB1—systemic lupus erythematosus	5.97e-06	4.75e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CDKN1B—systemic lupus erythematosus	5.48e-06	4.36e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—EP300—systemic lupus erythematosus	5.42e-06	4.31e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—IL2—systemic lupus erythematosus	5.36e-06	4.27e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—IL6—systemic lupus erythematosus	5.33e-06	4.24e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—MMP9—systemic lupus erythematosus	5.07e-06	4.04e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CDKN1A—systemic lupus erythematosus	5.06e-06	4.02e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—EP300—systemic lupus erythematosus	5.02e-06	3.99e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—IL6—systemic lupus erythematosus	4.87e-06	3.88e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—EP300—systemic lupus erythematosus	4.81e-06	3.83e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PPARG—systemic lupus erythematosus	4.76e-06	3.79e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—VEGFA—systemic lupus erythematosus	4.56e-06	3.62e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—IL6—systemic lupus erythematosus	4.55e-06	3.62e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—IL6—systemic lupus erythematosus	4.5e-06	3.58e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—ALB—systemic lupus erythematosus	4.28e-06	3.41e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—TGFB1—systemic lupus erythematosus	4.18e-06	3.33e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PPARG—systemic lupus erythematosus	4.15e-06	3.3e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—NOS3—systemic lupus erythematosus	4.09e-06	3.26e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—RXRA—systemic lupus erythematosus	4.05e-06	3.22e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PTGS2—systemic lupus erythematosus	3.74e-06	2.98e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—ALB—systemic lupus erythematosus	3.73e-06	2.97e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—NOS3—systemic lupus erythematosus	3.57e-06	2.84e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PTGS2—systemic lupus erythematosus	3.26e-06	2.6e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—IL6—systemic lupus erythematosus	3.15e-06	2.51e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—EP300—systemic lupus erythematosus	3.11e-06	2.48e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—EP300—systemic lupus erythematosus	2.71e-06	2.16e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PPARG—systemic lupus erythematosus	2.55e-06	2.03e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—ALB—systemic lupus erythematosus	2.3e-06	1.83e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—NOS3—systemic lupus erythematosus	2.2e-06	1.75e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PTGS2—systemic lupus erythematosus	2.01e-06	1.6e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—EP300—systemic lupus erythematosus	1.67e-06	1.33e-05	CbGpPWpGaD
